1. Search Result
Search Result
Results for "

SRF

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

4

Inhibitory Antibodies

1

Recombinant Proteins

2

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-118748

    SRF

    Microtubule/Tubulin Cancer
    Suprafenacine is a cell permeable, tubulin-destabilizing molecule which bind microtubules at the colchicine-binding site and inhibit polymerization. Suprafenacine can induce G2/M cell cycle arrest and apoptosis, and can be used for cancer research .
    Suprafenacine
  • HY-P990024

    SRF-388

    Interleukin Related Cancer
    Casdozokitug (SRF-388) is an IgG1κ antibody targeting IL27 .
    Casdozokitug
  • HY-P99533
    Urabrelimab
    1 Publications Verification

    SRF-231; SRF231

    CD47 Interleukin Related Cancer
    Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .
    Urabrelimab
  • HY-P990068

    SRF617

    NTPDase Inflammation/Immunology Cancer
    Perenostobart (SRF617) is a human IgG4 antibody with inhibitory activity against CD39 ATPase. Perenostobart inhibits CD39-mediated hydrolysis of extracellular ATP to AMP, with IC50 values of 1.9 nM (HEK293 OE cells), 0.7 nM (MOLP-8 cells), and 1.2 nM (RBC-lysed whole blood). Perenostobart enhances CD4 + T-cell proliferation, promotes dendritic cell maturation, and boosts inflammasome activation in macrophages in the presence of ATP. Perenostobart demonstrates significant single-agent anti-tumor efficacy in MOLP-8 and H520 xenograft models. Perenostobart can be used for the study of cancer .
    Perenostobart
  • HY-153078

    Ras Cancer
    MRTF/SRF-IN-1 (example 41) is an inhibitor of both myocardin-related transcription factor and serum response factor (MRTF/SRF). MRTF/SRF-IN-1 can be used for research for preventing cancer and fibrosis .
    MRTF/SRF-IN-1
  • HY-120855
    CCG-100602
    2 Publications Verification

    Ras Cardiovascular Disease
    CCG-100602 is a specific inhibitor of myocardin-related transcription factor A/serum response factor (MRTF-A/SRF) signaling. CCG-100602 specifically block MRTF-A nuclear localization and thus inhibit the fibrogenic transcription factor SRF .
    CCG-100602
  • HY-RS13760

    Small Interfering RNA (siRNA) Others

    SRF Human Pre-designed siRNA Set A contains three designed siRNAs for SRF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SRF Human Pre-designed siRNA Set A
    SRF Human Pre-designed siRNA Set A
  • HY-RS17529

    Small Interfering RNA (siRNA) Others

    Srf Mouse Pre-designed siRNA Set A contains three designed siRNAs for Srf gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Srf Mouse Pre-designed siRNA Set A
    Srf Mouse Pre-designed siRNA Set A
  • HY-RS23985

    Small Interfering RNA (siRNA) Others

    Srf Rat Pre-designed siRNA Set A contains three designed siRNAs for Srf gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Srf Rat Pre-designed siRNA Set A
    Srf Rat Pre-designed siRNA Set A
  • HY-P991061

    CHS-114; SRF-114

    CCR Cancer
    Tagmokitug (CHS-114) is a fully human IgG1 antibody that targets CCR8. Tagmokitug has the potential for the study of head and neck squamous cell carcinoma (HNSCC). The isotype control for Tagmokitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
    Tagmokitug
  • HY-108361
    CCG-203971
    1 Publications Verification

    Ras Inflammation/Immunology Cancer
    CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent .
    CCG-203971
  • HY-130011

    ROCK Ras Neurological Disease Cancer
    CCG-232964 is an orally active inhibitor of Rho/MRTF/SRF. CCG-232964 inhibits LPA-induced CTGF gene expression .
    CCG-232964
  • HY-13991
    CCG-1423
    Maximum Cited Publications
    13 Publications Verification

    Ras Apoptosis Cancer
    CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes .
    CCG-1423
  • HY-111432

    Ras Others
    CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibits the development of Bleomycin-induced dermal fibrosis in mice. CCG-232601 has the potential for the research of antifibrotic for systemic scleroderma .
    CCG-232601
  • HY-13991R

    Ras Apoptosis Cancer
    CCG-1423 (Standard) is the analytical standard of CCG-1423. This product is intended for research and analytical applications. CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes .
    CCG-1423 (Standard)
  • HY-162904

    Mitochondrial Metabolism Cardiovascular Disease
    BPU17 binds to PHB1 and causes mild defects in mitochondrial function by defects in the PHB1-PHB2 interaction. This impairment inhibits the SRF/CArG-box-dependent transcription, resulting in the suppression of epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells (RPEs). BPU17 exhibits antifibrotic activity in vivo. BPU17 is promising for research of anti-neovascular age-related macular degeneration (nAMD) agent .
    BPU17
  • HY-162968

    Ras Cardiovascular Disease Metabolic Disease
    MRTF-A-in-1 (Compound 14) is MRTF-A inhibitor. MRTF-A-in-1 can inhibit cell proliferation and induce HCC cell aging .
    MRTF-A-IN-1
  • HY-162969

    Ras Cardiovascular Disease Metabolic Disease
    MRTF-A-in-2 (Compound 16) is MRTF-A inhibitor. MRTF-A-in-1 can inhibit cell proliferation and induce HCC cell aging .
    MRTF-A-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: